My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 7 290 / https://doi.org/10.3332/ecancer.2013.290

Research

Antiemetic activity of volatile oil from Mentha spicata and Mentha × piperita in chemotherapy-induced nausea and vomiting

Background: This study is aimed at determining the efficacy of Mentha spicata (M. spicata) and Mentha × piperita (M. × piperita) in preventing chemotherapy-induced nausea and vomiting (CINV).

Methods: This was a randomised, double-blind clinical trial study. Prior to the study, patients were randomly assigned into four groups to receive M. spicata or M. × piperita. Statistical analysis included the χ2 test, relative risk, and Student’s t-test. Fifty courses were analysed for each group that met our eligibility criteria. The treatment and placebo groups applied essential oils of M. spicata, M. × piperita, or a placebo, while the control group continued with their previous antiemetic regimen. Patients or guardians recorded the number of emetic events, the intensity of nausea over 20 h of chemotherapy, as well as any possible adverse effects that occurred during this time.

Results: There was a significant reduction in the intensity and number of emetic events in the first 24 h with M. spicata and M. × piperita in both treatment groups (p < 0.05) when compared with the control and no adverse effects were reported. The cost of treatment was also reduced when essential oils were used.

Conclusion: M. spicata or M. × piperita essential oils are safe and effective for antiemetic treatment in patients, as well as being cost effective.

Keywords: chemotherapy-induced nausea and vomiting (CINV), essential oils, Mentha spicata, Mentha × piperita, Lamiaceae

Loading Article Metrics ... Please wait

Related articles

Conference Report: Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18–19 January 2018, Cairo, Egypt

Abstract | Full Article | PDF Published: 22 Mar 2018 / https://doi.org/10.3332/ecancer.2018.820

Conference Report: Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8–9 February 2018

Abstract | Full Article | PDF Published: 05 Mar 2018 / https://doi.org/10.3332/ecancer.2018.817

Research: MGMT promoter methylation in Peruvian patients with glioblastoma

Abstract | Full Article | PDF Published: 14 Feb 2018 / https://doi.org/10.3332/ecancer.2018.812

Short Communication: InforMD: a new initiative to raise public awareness about breast density

Abstract | Full Article | PDF Published: 06 Feb 2018 / https://doi.org/10.3332/ecancer.2018.807

Research: Knowledge and attitude of women regarding breast cancer screening tests in Eastern Iran

Abstract | Full Article | PDF Published: 05 Feb 2018 / https://doi.org/10.3332/ecancer.2018.806



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence